Hypothalamic-pituitary-adrenal (HPA) activity is governed by glucocorticoid negative feedback and the magnitude of this signal is determined, in part, by variations in plasma corticosteroid-binding globulin (CBG) capacity. Here, in gonadectomized male rats we examine the extent to which different testosterone replacement levels impact on CBG and HPA function. Compared with gonadectomized rats with low testosterone replacement ( 2 ng/ ml), plasma adrenocorticotropin and -endorphin/ -lipotropin responses to restraint stress were reduced in gonadectomized rats with high testosterone replacement ( 5 ng/ml). Plasma CBG levels also varied negatively as a function of testosterone concentration. Moreover, glucocorticoid receptor binding in the liver was elevated by higher testosterone replacement, suggesting that testosterone acts to enhance glucocorticoid suppression of CBG synthesis. Since pituitary intracellular CBG (or transcortin) is derived from plasma, this prompted us to examine whether transcortin binding was similarly responsive to different testosterone replacement levels. Transcortin binding was lower in gonadectomized rats with high plasma testosterone replacement ( 7 ng/ml) than in gonadectomized rats with low testosterone replacement ( 2 ng/ml). This testosterone-dependent decrease in pituitary transcortin was associated, in vitro, with an enhanced nuclear uptake of corticosterone. These findings indicate that the inhibitory effects of testosterone on corticotrope responses to stress may be linked to decrements in plasma and intrapituitary CBG. This could permit greater access of corticosterone to its receptors and enhance glucocorticoid feedback regulation of ACTH release and/or proopiomelanocortin processing.
Introduction
Hypothalamic-pituitary-adrenal (HPA) activity is regulated by a negative feedback process in which circulating glucocorticoids act at various target sites in the brain and pituitary to limit the secretion of adrenocorticotropin (ACTH). Corticosterone (the principal glucocorticoid in the rat) circulates either bound to its specific plasma binder corticosteroid-binding globulin (CBG) or in the free form. The amount of corticosterone that is taken up by target tissue is approximated by the non-CBG bound (free+albumin) fraction of total circulating steroid (Siiteri et al. 1982 , Pardridge et al. 1981 . Thus, differences in circulating CBG levels determine the magnitude of the glucocorticoid negative-feedback signal (Henning 1978 , Walker et al. 1986 . For example, CBG levels in the neonate are markedly reduced , resulting in a higher proportion of total circulating corticosterone in the free state which contributes to reduced ACTH responses to stress (Walker et al. 1986 (Walker et al. , 1990 . Circulating CBG levels are approximately twofold higher in adult female rats compared with males (Gala & Westphal 1965 , Keller et al. 1966 . This sex difference is attributed to androgenic effects in males, as treatment with testosterone or dihydrotestosterone (DHT), the reduced nonaromatizable derivative of testosterone, reverses the stimulatory effects of gonadectomy on plasma CBG (Gala & Westphal 1965 , Keller et al. 1966 , McCormick et al. 2002 , while estrogen elevates plasma CBG in male rodents (McCormick et al. 2002 ; but see Kurabekova et al. 1988) .
Within the brain and pituitary, glucocorticoid negative feedback inhibition of ACTH release is mediated by two corticosteroid receptor subtypes, including the mineralocorticoid and glucocorticoid receptors (reviewed in Dallman et al. 1987 , Jacobson & Sapolsky 1991 ; see also Reul & de Kloet 1985) . In addition to these receptors, numerous studies have identified the presence of intracellular CBG (or transcortin) in the anterior pituitary corticotrope (de Kloet & McEwen 1976 , Koch et al. 1976 . Pituitary transcortin binds corticosterone with high affinity, but unlike the corticosteroid receptors, does not translocate into the cell nucleus, effectively limiting the nuclear corticosterone signal (Sakly & Koch 1981 , 1983 . Decreased levels of transcortin in the pituitary have been associated, in vitro, with an enhanced nuclear accumulation of corticosterone and feedback inhibition of ACTH release (Sakly & Koch 1981 , Walker et al. 1986 ). This phenomenon is consistent with the exclusive distribution of CBG within corticotrope cells of the anterior pituitary (PerrotApplanat et al. 1984) . Thus, alterations in glucocorticoid feedback efficacy at the level of the corticotrope can be determined by the binding capacity of transcortin, independent of the corticosteroid receptors.
Plasma ACTH responses to stress are typically higher in female than in male rats (Le Mevel et al. 1978) . Since both plasma and pituitary CBG levels are lower in males, the sex difference in ACTH release during stress may possibly reflect a greater glucocorticoid feedback signal in the blood and pituitary in males. The present study extends our earlier findings showing that ACTH responses to stress vary inversely as a function of individual differences in circulating testosterone levels in gonadal-intact male rats, and in a dose-related inhibitory manner in testosteronereplaced gonadectomized male rats . Here, using gonadectomized rats we revisit the dose-related effects of testosterone on plasma and intrapituitary CBG, determining, in turn, how these effects on CBG could impact on stress-related HPA function.
Materials and Methods

Animals
Long-Evans hooded rats (Charles River Canada, St Constant, Quebec, Canada) were used, weighing approximately 300 g at testing. Rats were housed with food and drinking water available ad libitum. All rats were bilaterally gonadectomized (GDX) and immediately implanted with either one, two or three subcutaneous Silastic capsules (Dow Corning, Midland, MI, USA; each 25 mm length, 1·57 mm ID, 3·18 mm OD) filled with crystalline testosterone; the capsules were designed to provide circulating testosterone levels over the normal physiological range in a 300 g rat (Smith et al. 1977) . Plasma and tissue samples were obtained two weeks following castration and implantation of testosterone-filled capsules. Room temperature was maintained at 20-22 C with a 12 h light:12 h darkness schedule (lights on from 0800-2000 h). Hormone measures during restraint were obtained from blood samples collected from an indwelling right jugular vein silastic cannula (Dow Corning; 0·025 ID, 0·047 OD) exiting from the back of the neck, and replaced with an equal volume of normal saline (0·9%) via the same route. Jugular catheterizations were performed using the inhalation anesthetic Metofane (methoxyflurane; Pitman-Moore Inc., Washington Crossing, NJ, USA) four days prior to testing.
Restraint stress experiments
In all cases restraint stress was performed between 1200 and 1500 h. Prestress blood samples were taken from rats within 30 s of removal from the cage. Rats were then immediately placed in restrainers for a period of 10 min, after which blood was sampled at 0, 10, 20, 30, and 60 min post stress. Blood samples (300 µl) were collected in iced tubes containing 10 µl EDTA and Trasylol (aprotinin; Miles Laboratories, Mississauga, Ontario, Canada), centrifuged at 3000 g for 10 min, and stored at 80 C until assayed. All protocols were approved by the Animal Care Committee of McGill University and the University of British Columbia.
Plasma CBG assay
Plasma CBG was measured by a method similar to that of Martin et al. (1977) . Endogenous steroids were removed from plasma samples by passing the plasma through Sephadex LH-20 (Pharmacia Fine Chemicals, Dorval, Quebec, Canada) columns (7 1 cm) and diluting the eluents 1:50 (v/v) in 30 mM Tris, 1 mM EDTA, 10 mM sodium molybdate, 10% v/v glycerol, and 1 mM dithiothreitol (TEDGM; pH adjusted to 7·4). Diluted plasma (225 µl) was incubated in the presence of 80 nM [ 3 H]corticosterone overnight at 0 C with or without a 200-fold excess of unlabeled corticosterone (total and non-specific binding respectively). A fraction of the diluted plasma was assayed for protein content. Following the incubation, separation of bound from free ligand was performed using Sephadex LH-20 columns equilibrated with TEDGM. The incubates (100 µl) were washed onto the columns with 100 µl TEDGM. The columns were then eluted 30 min later with 500 µl TEGM, and collected into mini-vials which were then filled with 5 ml Liquiscent (National Diagnostics, Somerville, NJ, USA), and counted in a Packard scintillation counter. Plasma CBG values are expressed as nM concentrations.
Intrapituitary CBG (transcortin) assay
Transcortin binding sites were determined as previously described (Meaney et al. 1985) . Briefly, whole pituitaries were homogenized in TEDGM and then centrifuged for 60 min at 105 000 g. Protein concentrations of the supernatants were determined using the method of Bradford (1976) . The soluble fraction was then incubated at 0 C for 22 h with a saturating concentration of [ 3 H]corticosterone (20 nM) and a 500-fold excess of unlabeled dexamethasone (DEX; to preclude binding to glucocorticoid receptor sites) with or without a 200-fold excess of unlabeled corticosterone. Incubates were chromatographed on Sephadex LH-20 as described for the plasma CBG assay. Results are expressed as fmol/mg protein.
Hepatic corticosteroid receptors
Tissue was obtained from a separate group of testosteronereplaced gonadectomized rats killed by decapitation 16 h following adrenalectomy to allow for adequate clearance of corticosterone. Liver fragments were quickly dissected and stored at 80 C until assayed. The tissue was homogenized in TEDGM and centrifuged for 60 min at 105 000 g. Protein concentrations of the supernatants were determined using the method of Bradford (1976) . Single point glucocorticoid receptor binding assays were performed by incubating 225 µl aliquots of the soluble fraction with 150 µl of a saturating 10 nM concentration of [ 3 H]DEX (88·7 µCi/mmol, New England Nuclear, Boston, MA, USA) with or without a 200-fold excess of the glucocorticoid receptor agonist RU28362. RU28362 binds selectively to the glucocorticoid receptor, showing very little affinity for the mineralocorticoid receptor (Coirini et al. 1985 , Reul & de Kloet 1985 . Mineralocorticoid receptor determinations were performed by incubating the soluble fractions with 150 µl of a saturating 7 nM concentration of [ 3 H]corticosterone (88·0 µCi/ mmol, New England Nuclear) with a 25-fold excess of RU28362, with or without a 200-fold excess of aldosterone. Following a 24 h and 48 h incubation at 0 C for mineralocorticoid and glucocorticoid receptors respectively, separation of bound from free ligand was performed on Sephadex LH-20 columns, after which the bound fraction was counted, as discussed above. The specific binding is expressed as fmol/mg protein.
Anterior pituitary [ 3 H]corticosterone nuclear uptake
Pituitaries were obtained from the same groups of testosterone-replaced gonadectomized rats used in the hepatic corticosteroid receptor study, likewise killed by decapitation 16 h following adrenalectomy. As previously described (Koch et al. 1974) , anterior pituitaries were homogenized in buffer containing 0·01 M MgCl 2 , 0·025 M KCl and 0·002 M dithiothreitol (pH 7·4). Protein concentrations of the homogenates were determined using the method of Bradford (1976) . Homogenates were then incubated at 25 C in the presence of either 10 or 100 nM [ 3 H]corticosterone. Non-specific uptake was determined in parallel incubations containing a 200-fold excess of unlabeled corticosterone. The homogenates were then centrifuged at 600 g for 10 min and the resulting pellet was then resuspended and centrifuged (600 g) in homogenate buffer supplemented with 0·2% v/v Triton X-100 and 0·25 M sucrose. The crude nuclear fraction was then obtained following three successive resuspensions and centrifugations in homogenate buffer supplemented with 0·32 M sucrose. Radioligand was then extracted from the nuclear pellet with 1 ml ethanol and counted. Specific nuclear uptake is expressed as fmol/mg protein.
Radioimmunoassays
Plasma (10 µl) corticosterone was measured by RIA using a highly specific corticosterone antiserum (B3-163, Endocrine Sciences, Tarzana, CA, USA) and [
3 H]corticosterone (101 Ci/mmol, New England Nuclear) as tracer, as previously described (Viau et al. 1993 . Briefly, 10 µl plasma samples were extracted in 1 ml ice-chilled ethanol, and then centrifuged for 10 min at 3000 g. Duplicate 100 µl aliquots of each supernatant were vacuum dried, and then reconstituted and incubated overnight in 100 µl phosphate-buffered saline containing corticosterone antisera (diluted 40 µl/ml PBS) and 100 µl [ (15 10 3 c.p.m. per 100 µl PBS) at 4 C. After 24 h, separation of bound from free corticosterone was achieved by incubating the samples in PBSdextran-coated charcoal for 15 min, then centrifuged for 10 min at 3000 g. Finally, 1 ml of the supernatant (free fraction) was counted in 5 ml scintillation cocktail. The antiserum cross-reacts slightly with desoxycorticosterone ( 4%), but not with aldosterone, cortisol or progesterone (,1%). The detection limit of the assay was 10 ng/ml. The intra-and interassay coefficients of variation were 8·8 and 10·4% respectively.
The free or non-CBG-bound fraction of total corticosterone was calculated from the total molar concentrations of corticosterone and CBG using a variation of a mass action equation (Plymate et al. 1987) , and employing the dissociation constant of corticosterone and CBG (K d 13 nM). This calculation has been validated with direct measures of free steroid, as seen by the relationship between free, total, and sex hormone-binding globulinbound testosterone concentrations (see Plymate et al. 1989) . Further, individual differences in plasma CBG levels, as detected by the plasma CBG binding method used in the present study, are met by parallel differences in free corticosterone levels measured directly , Tannenbaum et al. 1997 .
Plasma (25 µl) testosterone was measured using the RIA kit of ICN-Biomedicals (Carson, CA, USA) with [ 125 I] testosterone as tracer. The testosterone antibody (solid phase) cross-reacts slightly with 5 -dihydrotestosterone (7·8%), 5 -androstane-3 , 17 -diol (2·2%) and 11-oxotestosterone (2%), but does not cross-react with progesterone, estrogen, or with the glucocorticoids (all ,0·01%). The detection limit of the assay was 0·6 ng/ml. The intra-and interassay coefficients of variation were 3·5 and 10·0% respectively. Plasma (25 µl) ACTH concentrations were measured by RIA as previously described (Viau et al. 1993) . Briefly, unextracted plasma was incubated overnight at 4 C with a specific ACTH antiserum at a final dilution of . After 48 h of further incubation, precipitation serum (Antibodies Inc., Davis, CA, USA) was added and bound peptide was obtained by centrifugation at 5000 g for 45 min. The detection limit of the assay was 10 pg/ml. The intra-and interassay coefficients of variation were 7·5 and 12·0% respectively.
Plasma -END/ -LPH was determined by RIA from 25 µl unextracted plasma as previously described (Iny et al. 1987 ) using an antiserum specific for the C-terminus of -endorphin1-31 ( -END) at a final dilution of 1:30 000 and [
125 I] -END1-31 as tracer (12 000 c.p.m./tube). The -END antibody cross-reacts 100% with -lipotropin ( -LPH) and -N-acetylated -END, 70% with -END1-27, but not with ACTH, -MSH, -MSH, nor with -LPH fragments 61-65, 62-67 and 80-84. The detection limit of the assay was 10 pg/ml. The intra-and interassay coefficients of variation were 8·6 and 9·8% respectively. Plasma ACTH and -END/ -LPH values were expressed in pM concentrations, permitting direct molar comparisons in their release profiles.
Integrated ACTH and -END/ -LPH (pM/min) responses were derived using the area under the curve (AUC) trapezoidal method (Tallarida & Murray 1981) , in which the area under each temporal segment was totalled and averaged over the entire 70 min sampling period. Stress peak integral ACTH and -END/ -LPH levels were determined by subtracting peak from basal plasma hormone values (see Table 1 ). Finally, the ratio of -END/ -LPH:ACTH was used to provide an index of the relative release profile of these peptides.
Statistical analysis
Data were analyzed using analysis of variance (ANOVA). Tukey post-hoc tests were used, where appropriate, to explore the source of significant effects. Statistical and regression analyses were performed using Statview (Power PC version 5·01, Cary, NC, USA).
Results
Plasma testosterone replacement
Plasma testosterone replacement levels in GDX male rats approximated the physiological range seen in gonadal intact male rats. The variation in plasma testosterone concentrations produced was ample enough to demonstrate the dose-related nature by which testosterone normally operates on HPA function (Fig. 1) . To illustrate this feature, rats were grouped based on their individual testosterone levels, either above or below the median testosterone level of 2·7 ng/ml. Thus, as groups, the mean testosterone concentrations were 5·1 0·6 ng/ml (GDX+high T) and 1·7 0·3 ng/ml (GDX+low t). The data presented in Figs 2-4 and in Table 1 were determined from these testosterone-replaced GDX rats. The final two studies examining hepatic corticosteroid receptors and pituitary nuclear uptake (Figs 5 and 6 respectively) were derived from separate groups of testosterone-replaced GDX rats, in which the mean plasma testosterone concentrations were 7·6 0·7 ng/ml (GDX+high T) and 2·5 0·5 ng/ml (GDX+low t).
Plasma ACTH and -END/ -LPH responses to restraint
Relative to GDX rats replaced with low testosterone levels, GDX rats with higher plasma testosterone concentrations showed reduced ACTH and -END/ -LPH responses over the entire testing period (Fig. 2) . This was attributed to testosterone-dependent differences in peak ACTH and -END/ -LPH levels, achieved at the end of restraint exposure (see Stress peak integral, Table 1 ). No significant differences were found in pre-stress levels of ACTH and -END/ -LPH. Independent of testosterone, the -END/ -LPH:ACTH ratio was highest under basal conditions, and nearly 1:1 during restraint-stress Figure 1 Individual plasma testosterone levels in GDX male rats with subcutaneous testosterone implants. Ranked according to plasma steroid concentrations, the median testosterone value was 2·6 ng/ml. Rats with testosterone levels greater or less than this value were grouped as GDX high testosterone (T) or GDX low testosterone (t) respectively (n=13 rats per group).
(see Ratio, Table 1 ). This is consistent with previous studies using antisera identical to our own, showing that circulating endorphins dominate over ACTH under basal conditions, approaching uniformity under stress conditions (De Souza & Van Loon, 1985 , Van Loon & De Souza 1987 . The latter is in line with the fact that -LPH, originating from anterior pituitary corticotropes, is the principal endorphin secreted during acute stress exposure. The -END/ -LPH:ACTH ratio varied as a function of testosterone replacement, however, being significantly lower in GDX+high testosterone replaced rats than in GDX+low testosterone replaced rats (see Stress peak integral ratio, Table 1 ).
Plasma CBG and free corticosterone responses to restraint stress
Plasma CBG levels were reduced in GDX rats replaced with higher testosterone replacement levels (see Fig. 3 inset). Despite this difference in plasma CBG, and owing to a larger disparity in total hormone released, free corticosterone levels remained relatively lower in GDX+high than GDX+low testosterone replaced rats (Fig. 3) . Basal free corticosterone concentrations did not vary as a function of testosterone replacement (free -LPH responses to 10 min of restraint stress in GDX+high T and in GDX+low t replaced rats (n=13 rats per group). **P<0·01 compared with GDX rats with low testosterone replacement. Absolute plasma levels at termination of 10 min restraint; 2 difference between basal and peak values; **P<0·01, *P<0·05, GDX+high T vs GDX+low t.
Figure 3
Mean ( S.E.M.) free plasma corticosterone (B) responses to 10 min of restraint stress in GDX+high T and in GDX+low t replaced rats. Inset: mean ( S.E.M.) plasma CBG levels (n=13 rats per group). *P,0·05, **P,0·01 compared with GDX rats with low testosterone replacement.
corticosterone=3·6 0·6 nM and 3·4 0·8 nM in high and low testosterone-replaced rats respectively).
Intrapituitary CBG (transcortin)
Pituitary transcortin levels paralleled the effects of testosterone on plasma CBG (Fig. 4) . Thus, transcortin binding was reduced in GDX rats replaced with higher testosterone levels. Regression analysis indicated a strong negative relationship (r=0·66; P=0·0011) between transcortin binding and individual plasma testosterone concentrations (Fig. 4, top) . Transcortin binding also varied strongly and positively as a function of plasma CBG (Fig. 4 bottom,   r=0·80 ; P,0·0001). In both cases, the relationships were best described using a 2nd order polynomial fit.
Corticosteroid receptor binding in liver
Analysis of hepatic corticosteroid receptor levels as a function of testosterone replacement revealed no significant differences in mineralocorticoid receptor binding (Fig. 5) . However, glucocorticoid receptor binding varied as a function of testosterone replacement. As a group, GDX rats replaced with higher plasma testosterone (7·6 0·7 ng/ml) showed greater glucocorticoid receptor binding than GDX rats replaced with lower testosterone (2·5 0·5 ng/ml) (Fig. 5 ).
Anterior pituitary [ 3 H]corticosterone nuclear uptake
To examine how androgen-dependent differences in anterior pituitary transcortin binding could alter glucocorticoid uptake, pituitaries obtained from rats with high and low plasma testosterone levels were incubated in vitro with [ 3 H]corticosterone concentrations approximating either basal (10 nM) or stress (100 nM) concentrations of free corticosterone. At 10 nM, there were no differences in [ 3 H]corticosterone nuclear uptake (Fig. 6) . However, at 100 nM, the nuclear uptake of [ 3 H]corticosterone was significantly greater (P,0·01) in pituitaries from GDX rats with high plasma testosterone replacement than in GDX rats with low testosterone replacement (Fig. 6 ).
Discussion
The dose-related inhibitory effects of testosterone on corticotrope responses to stress may be linked to decrements in plasma and intrapituitary CBG. Similar to our current findings, decreased intrapituitary CBG (or transcortin) has been associated with an increased nuclear uptake of corticosterone in vitro, and enhanced glucocorticoid inhibition of ACTH release in vivo (Sakly & Koch 1981 , 1983 . In GDX rats receiving higher testosterone replacement levels, the nuclear uptake of [ 3 H]corticosterone was elevated in pituitaries at a concentration of 100 nM, but not at 10 nM. This testosterone-dependent difference in the nuclear uptake of corticosterone is reflective of a functional change in the dynamics of transcortin and not corticosteroid receptor activity. Sex differences in corticosteroid receptor binding at the level of the anterior pituitary have not been reported (Ferrini et al. 1990 , Burgess & Handa, 1992 . Further, mineralocorticoid and glucocorticoid receptor binding in the anterior pituitary do not vary as a function of androgen replacement in gonadectomized rats replaced with DHT or testosterone (Handa et al. 1994 . The fact that the nuclear uptake of corticosterone was distinguished with 100 nM but not with 10 nM corticosterone is, on the one hand, consistent with the relatively lower affinity of transcortin for corticosterone compared with corticosteroid receptors (10 nM vs 0·5-2·5 nM respectively). On the other hand, changes in transcortin binding may only be relevant to periods of increased HPA drive either during the circadian peak in basal HPA activity or during stress when free corticosterone concentrations approximate or exceed 100 nM.
In addition to ACTH, GDX rats with higher testosterone replacement levels displayed reduced -END/ -LPH responses to restraint, indicating similar inhibitory influences of testosterone on the stimulated release of proopiomelanocortin (POMC)-related peptides. Chromatographic analyses using antisera identical to our own indicate that while -END derived from intermediate lobe melanotropes represents the principal source of circulating endorphins under basal conditions, -LPH release from the anterior pituitary dominates over -END in response to acute stress (De Souza & Van Loon, 1985 , Van Loon & De Souza 1987 . Given the shift in the ratio of -END/ -LPH:ACTH secreted during restraint as a function of testosterone replacement, reduced in rats with higher testosterone replacement, it is tempting to speculate a role for testosterone (and transcortin) in regulating POMC processing in response to acute stress. However, because the relative contributions of -END and -LPH were not determined in the present study, the extent to which the findings speak of changes in POMC processing or the source of endorphins secreted remains unresolved. Notwithstanding this limitation, what merits some attention are previous studies identifying even greater disparities between -LPH and ACTH secretion under more chronic stress conditions. Repeated restraint potentiates -LPH release, without affecting the magnitude of the -END and ACTH responses (De Souza & Van Loon 1985 , Van Loon & De Souza 1987 . Interestingly, this potentiating effect on -LPH is eliminated by adrenalectomy (ADX), indicating that the inhibition of -LPH processing may be glucocorticoid dependent (see De Souza & Van Loon 1989) . Since testosterone secretion varies in response to repeated stress, testosterone-dependent alterations in pituitary CBG and corticosterone uptake may play a greater role in POMC processing under more chronic or repeated stress conditions.
In anterior pituitary cells, CBG is found in membrane fractions in addition to the cytosol compartment (Koch et al. 1978) . Membrane-bound and cytosolic CBG (transcortin) levels in the pituitary have both been shown to parallel the changes in circulating CBG concentrations (Koch et al. 1978 , Tannebaum et al. 1997 . Interestingly, binding of corticosterone to hypothalamic membrane fractions is absent in perfused mice (Orchinik et al. 1991) . Thus, membrane-bound CBG may possibly reflect the transit of the globulin through the membrane as it diffuses into the cell. Our data also indicate a parallel relationship between pituitary transcortin and plasma CBG concentrations. However, transcortin binding failed to increase beyond plasma CBG levels of 1000 nM (see Fig. 4, bottom panel) . This would suggest that CBG diffusion across cell membranes is a saturable process. Considering the dual inhibitory effects of testosterone on plasma CBG and transcortin, it is likely that membranebound CBG receptor levels are also affected. Given the Figure 6 Specific nuclear uptake of [ 3 H]corticosterone ( 3 H-B; 10 and 100 nM), in vitro, in anterior pituitaries from GDX+high T and from GDX+low t replaced rats (n=7 per group). **P,0·01 compared with GDX rats with low testosterone replacement.
proposed role for membrane-bound CBG in mediating rapid glucocorticoid effects on cellular activity (see Orchinik et al. 1991) , it is attractive to speculate that testosterone may also modulate the nontranscriptional actions of corticosterone.
Plasma CBG shows a diurnal rhythm in circulating levels, rising in the p.m. and declining during the a.m. period in the rat (Hsu & Kuhn 1988 , Meaney et al. 1992 . This rhythm, however, is not re-instated in ADX rats provided with corticosterone in their drinking water, a replacement regimen which mimics the diurnal corticosterone rhythm (Hsu & Kuhn 1988) . Thus, circulating glucocorticoids appear to regulate the range, but not the diurnal rhythm in plasma CBG. It is important to note that ADX also causes a decrease in plasma testosterone levels (Viau et al. 1999) . Moreover, testosterone secretion in males cycles in a manner which reciprocates the daily rhythm of CBG and corticosterone release (Kalra & Kalra 1977 , Plymate et al. 1989 , Winters et al. 1991 . Finally, the diurnal rhythm in cortisol levels is abolished by GDX in male primates (Smith & Norman 1987) . Taken together, these findings suggest that the diurnal pattern in CBG synthesis and release is multifactorial and, at the very least, sensitive to corticosterone and testosterone interactions. Since hepatic production of CBG is inhibited by glucocorticoids directly (Dallman et al. 1987 , Levin et al. 1987 , a critical point of this adrenal-gonadal interaction on CBG appears to reside at the level of the hepatic glucocorticoid receptor. This is indicated by the positive effect of increasing testosterone replacement levels on glucocorticoid receptor binding in the liver, suggesting that glucocorticoid suppression of CBG synthesis may be enhanced by testosterone.
The dose-related effects of testosterone on hepatic glucocorticoid receptors and presumably on CBG synthesis and release should not be underestimated, revealing additional mechanisms by which the adrenal and gonadal systems interact (reviewed by Viau 2002) . In keeping with this interactive nature, we have previously shown that corticosterone inhibition of acute stressinduced ACTH release is reduced by gonadectomy and restored with testosterone replacement (Viau et al. 1999) , and that this likely involves testosterone-and corticosterone-dependent changes in paraventricular nucleus (Viau et al. 2001 (Viau et al. , 2003 . Since changes in CBG synthesis and capacity can effectively alter glucocorticoid receptor occupancy in the brain and, as shown here, in the pituitary, corticotrope responses to acute stress may reflect a balance between effects on secretagogue release centrally and corticotrope responses peripherally. As acute stress exposure produces long-term changes in both plasma and pituitary CBG (Tannenbaum et al. 1997) , plasma testosterone levels at the time of acute stress could have enduring effects on how the HPA axis responds to subsequent stress exposure (see van Dijken et al. 1993) .
